A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific antibody therapy, enabling outpatient treatment and improving patient ...
BALTIMORE — The anti-interleukin-6 (IL-6) antibody drug tocilizumab shows efficacy in the treatment of patients with autoimmune limbic encephalitis (ALE) who do not respond to rituximab, new research ...
Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a ...
Long-term treatment with tocilizumab was effective in patients with moderate-to-severe thyroid eye disease (TED) that was resistant to corticosteroids, with 58% of patients achieving clinical ...
Reply to: Random Assignment, But Without Comparison: A Missed Opportunity The article by Chen et al entitled “Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results